NDAORALTABLET
Approved
Jul 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
ZEBETA (bisoprolol fumarate) by Teva is clinical pharmacology bisoprolol fumarate tablets are a beta 1 -selective (cardioselective) adrenoceptor blocking agent without significant membrane stabilizing activity or intrinsic sympathomimetic activity in its therapeutic dosage range. First approved in 1992.
Drug data last refreshed 16h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZEBETA (bisoprolol fumarate) is a beta-1 selective (cardioselective) adrenergic blocking agent approved in 1992 for the treatment of hypertension and angina. It works by reducing heart rate and cardiac output through selective inhibition of beta-1 receptors, with cardioselectivity maintained at therapeutic doses (5–20 mg daily).
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30%), indicating a mature brand transitioning toward loss of exclusivity with likely contraction in team size and budget allocation.
Mechanism of Action
CLINICAL PHARMACOLOGY Bisoprolol fumarate tablets are a beta 1 -selective (cardioselective) adrenoceptor blocking agent without significant membrane stabilizing activity or intrinsic sympathomimetic activity in its therapeutic dosage range. Cardioselectivity is not absolute, however, and at higher…
Worked on ZEBETA at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.